Peptides DB
Research-centric peptide and protocol reference hub
Study 35 of 36Octreotide literatureJournal of diabetes and metabolic disorders · Case report2026

Bilateral pheochromocytoma and multiple paragangliomas in a patient with a heterozygous <i>SDHD</i> mutation: A challenging case report.

This case illustrates the challenges in managing hereditary pheochromocytoma and paraganglioma, particularly with the loss of response to octreotide therapy after one year.

Read at Journal of diabetes and metabolic disordersAdd to compare

Where it sits

this study against the rest of the octreotide corpus
1
Preclinical
30
Observational · this one
0
Open-label
3
Randomised
2
Reviews

Summary and findings

A 26-year-old man with hereditary pheochromocytoma and paraganglioma underwent genetic testing that confirmed an SDHD mutation. Plasma normetanephrine was 2616 ng/L, and after initial treatment, a loss of therapeutic response to octreotide was observed one year post-initiation. The case highlights the complexities of managing multifocal disease in young patients.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Plasma normetanephrine was 2616 ng/L (13 times the upper normal limit).2026

Abstract

The authors’ words, as Journal of diabetes and metabolic disorders supplied them

Hereditary pheochromocytoma and paraganglioma (PPGL) are rare, genetically determined neuroendocrine tumors that often present at a young age. Their multifocal nature poses diagnostic and therapeutic challenges and warrants early genetic testing. A 26-year-old man was referred for cervical and mediastinal paragangliomas. Computed tomography scan revealed multiple cervical and mediastinal paragangliomas and bilateral pheochromocytoma. Plasma normetanephrine was 2616 ng/L (13 times the upper normal limit). Genetic testing confirmed an <i>SDHD</i> mutation. After alpha- and beta-blockade, the patient underwent bilateral adrenalectomy and mediastinal paraganglioma resection under cardiopulmonary bypass. Octreotide therapy was initiated due to inoperability of cervical paragangliomas.However, a loss of therapeutic response was observed one year after the initiation of somatostatin analogue. Radiotherapy was then considered for the cervical paragangliomas. This case underlines the complexity of PPGL management in patients with <i>SDHD</i> mutation. Multifocal disease demands individualized, multidisciplinary strategies and long-term follow-up to minimize morbidity and optimize outcomes in young patients.

Background

This paper addresses the management challenges of hereditary pheochromocytoma and paraganglioma (PPGL), particularly in patients with genetic mutations such as SDHD. Prior knowledge indicates that these tumors often present early and can be multifocal, complicating diagnosis and treatment. Understanding the implications of genetic testing and the role of therapies like octreotide in these cases is crucial for optimizing patient outcomes.

Methods

The study describes a case report of a 26-year-old male patient with cervical and mediastinal paragangliomas and bilateral pheochromocytoma. Genetic testing confirmed an SDHD mutation. The patient underwent bilateral adrenalectomy and mediastinal paraganglioma resection after alpha- and beta-blockade, followed by octreotide therapy due to the inoperability of cervical paragangliomas.

Results

Plasma normetanephrine was 2616 ng/L, which is 13 times the upper normal limit. A loss of therapeutic response to octreotide was observed one year after treatment initiation.

Interpretation

The findings highlight the complexities in managing PPGL, especially with genetic factors influencing treatment response. While the plasma normetanephrine level indicates significant tumor activity, the loss of response to octreotide after one year suggests that this treatment may not provide long-term efficacy for all patients. The case underscores the need for individualized treatment strategies and the importance of ongoing monitoring.

Key findings

  • Plasma normetanephrine was 2616 ng/L (13 times the upper normal limit).
  • Loss of therapeutic response to octreotide observed one year after initiation.

Limitations

  • Not reported in abstract.

Elsewhere in the Octreotide corpus

CMineralocorticoid receptor signaling reduces somatostatin expression in developing sensory neurons and drives neonatal pain after early-life stress.Pain · Not reported in abstract.AnimalBCongenital hyperinsulinism as part of a multisystem disease caused by a compound heterozygous variant in the <i>YARS1</i> gene.JCEM case reports · 2023 · n=1 · Not reported in abstract.HumanBManagement of Chylous Acid in Gynecological Malignanciesbiorxiv-preprint · 2026 · On postoperative day 4, median drainage output in TPN-requiring patients was 830 mL.HumanCThe role of biorelevant media components on the diffusion and enzymatic stability of oral cyclic peptide analogs.International journal of pharmaceutics · 2026 · Not reported in abstract.In vitroCActivation of the dopamine D2 receptor enhances colonic motility via disinhibition of somatostatinergic signalling in rodents.European journal of pharmacology · 2026 · Not reported in abstract.AnimalBMetastatic proinsulin-secreting tumor: a rare cause of persistent hypoglycemia.JCEM case reports · 2023 · n=1 · Not reported in abstract.Human